What is Carevive STAIRS and how does it impact patients and care teams?

Maddie Herzfeld, one of the co-founders of Carevive, excitedly announces the launch of Carevive STAIRS – the first-ever computerized cancer symptom pathways designed specifically for oncology nurses.

As an oncology nurse herself for the past 25 years, Maddie takes immense pride in this innovative product that empowers nurses to work at the top of their license. Carevive STAIRS, developed with input from expert oncology nurse panels across the country, enables early symptom detection and proactive management using the latest evidence, thereby preventing treatment disruptions and hospitalizations.

The product’s development was supported by the National Cancer Institute, and Carevive extends gratitude to the dedicated oncology nurses and their exceptional team who brought this groundbreaking tool to life. To see the difference Carevive STAIRS can make in your cancer program, reach out to their sales team for a demo. Get ready to elevate your patient care with Carevive STAIRS!

Recent Episodes

In this impactful episode of the ConCensis podcast, host Yasmeen Hassan sits down with Robby Miller, Sterile Processing Manager at St. Joseph’s Hospital Medical Center, to explore how artificial intelligence is revolutionizing the field of sterile processing. With nearly 30 years of experience in healthcare, Miller shares his journey from EMT to SPD leader, offering…

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

In an era where precision and predictability define the future of oncology, organoid technology is emerging as a transformative tool in drug discovery. These miniature, lab-grown 3D tissues mirror real human biology more closely than traditional 2D models or even animal systems, offering researchers the potential to predict patient-specific drug responses. As organoids become more…